Kamyar Kalantar-Zadeh M.D. to Hyperparathyroidism, Secondary
This is a "connection" page, showing publications Kamyar Kalantar-Zadeh M.D. has written about Hyperparathyroidism, Secondary.
Connection Strength
5.797
-
The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD. J Med Econ. 2020 Mar; 23(3):308-315.
Score: 0.643
-
Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2018 06 07; 13(6):952-961.
Score: 0.569
-
Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients. J Ren Nutr. 2016 07; 26(4):265-9.
Score: 0.498
-
Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis. 2012 Jan; 59(1):58-66.
Score: 0.362
-
Diuretics and secondary hyperparathyroidism in chronic kidney disease. Nephrol Dial Transplant. 2011 Apr; 26(4):1122-5.
Score: 0.352
-
Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients. Nephron Clin Pract. 2009; 113(1):c54-61.
Score: 0.312
-
Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2009 Mar; 4(3):673-9.
Score: 0.305
-
Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story. Am J Kidney Dis. 2009 Feb; 53(2):183-8.
Score: 0.303
-
Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients. Curr Med Res Opin. 2008 Nov; 24(11):3037-48.
Score: 0.296
-
Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2008 Nov; 3(6):1769-76.
Score: 0.293
-
Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008 Jun; 73(11):1296-302.
Score: 0.285
-
Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int. 2008 Jun; 73(12):1355-63.
Score: 0.284
-
Obesity is associated with secondary hyperparathyroidism in men with moderate and severe chronic kidney disease. Clin J Am Soc Nephrol. 2007 Sep; 2(5):1024-9.
Score: 0.273
-
Survival differences between activated injectable vitamin D2 and D3 analogs. Kidney Int. 2007 Apr; 71(8):827; author reply 827-8.
Score: 0.267
-
Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr. 2007 Jan; 17(1):38-44.
Score: 0.262
-
Clinical uses of 1-alpha-hydroxy-ergocalciferol. Curr Vasc Pharmacol. 2014 Mar; 12(2):306-12.
Score: 0.108
-
Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. Pharmacoepidemiol Drug Saf. 2012 Nov; 21(11):1232-9.
Score: 0.097
-
Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010 Aug; (117):S10-21.
Score: 0.084
-
Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol. 2008 Nov; 19(11):2193-203.
Score: 0.073
-
Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract. 2008 Jan-Feb; 14(1):18-27.
Score: 0.070
-
Risks of chronic metabolic acidosis in patients with chronic kidney disease. Kidney Int Suppl. 2005 Jun; (95):S21-7.
Score: 0.059